Claims
- 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) an isolated polynucleotide comprising nucleotides 1289 to 2464 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon; (b) an isolated polynucleotide comprising nucleotides 1286 to 2464 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon; and (c) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(b), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
- 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises a nucleotide sequence encoding a G-protein coupled receptor protein.
- 3. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 4. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 5. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
- 6. A recombinant host cell produced by the method of claim 5.
- 7. The recombinant host cell of claim 6 comprising vector sequences.
- 8. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) comprising amino acids 2 to 393 of SEQ ID NO:2, wherein said amino acids 2 to 393 comprise a polypeptide of SEQ ID NO:2 minus the start methionine; and (b) a polypeptide comprising amino acids 1 to 393 of SEQ ID NO:2.
- 9. The isolated polypeptide of claim 8, wherein the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
- 10. An isolated antibody that binds specifically to the isolated polypeptide of claim 9.
- 11. A recombinant host cell that expresses the isolated polypeptide of claim 8.
- 12. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 11 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide.
- 13. The polypeptide produced by claim 12.
- 14. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 8 or the polynucleotide of claim 1.
- 15. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
- 16. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
(a) determining the presence or amount of expression of the polypeptide of claim 8 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
- 17. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
(a) contacting the polypeptide of claim 11 with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide.
- 18. A method of identifying an activity in a biological assay, wherein the method comprises:
(a) expressing SEQ ID NO:1 in a cell; (b) isolating the supernatant; (c) detecting an activity in a biological assay; and (d) identifying the protein in the supernatant having the activity.
- 19. A peptide modulator of HGPRBMY14 biological activity comprising a polypeptide having a polypeptide sequence selected from the group consisting of SEQ ID NO:87, 88, 89, 90, or 91.
- 20. An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) an isolated polynucleotide comprising nucleotides 1289 to 2464 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon; and (b) an isolated polynucleotide comprising nucleotides 1286 to 2464 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon.
- 20. The isolated nucleic acid molecule of claim 20 wherein the polynucleotide comprises a nucleotide sequence encoding a G-protein coupled receptor protein.
- 21. The isolated nucleic acid molecule of claim 21, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 22. A recombinant vector comprising the isolated nucleic acid molecule of claim 20.
- 23. A recombinant host cell comprising the recombinant vector of claim 23.
- 24. An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:
(a) comprising amino acids 2 to 393 of SEQ ID NO:2, wherein said amino acids 2 to 393 comprise a polypeptide of SEQ ID NO:2 minus the start methionine; and (b) a polypeptide comprising amino acids 1 to 393 of SEQ ID NO:2.
- 26. A method of screening for candidate compounds capable of binding to and/or modulating activity of a G-protein coupled receptor, comprising:
a.) contacting a test compound with a substantially or partially purified polypeptide according to claim 8; and b.) selecting as candidate compounds those test compounds that bind to and/or modulate activity of the polypeptide.
- 25. The method according to claim 26, wherein the candidate compounds are small molecules.
- 26. A cell comprising NFAT/CRE and the polypeptide of claim 8.
- 27. A cell comprising NFAT G alpha 15 and the polypeptide of claim 8.
- 29. A method of screening for candidate compounds capable of modulating activity of a G-protein coupled receptor-encoding polypeptide, comprising:
(a) contacting a test compound with the cell according to claim 28; and (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.
- 30. The method according to claim 29, wherein the candidate compounds are agonists of G-protein coupled receptor activity.
- 31. The method according to claim 29, wherein the candidate compounds are antagonists of G-protein coupled receptor activity.
- 32. The cell according to claim 28 wherein the HGPRBMY14 polypeptide is expressed at low, intermediate, or high levels of expression.
- 33. A method of treating a disorder related to aberrant NF-kB activity comprising the step of administering an antagonist of the polypeptide provided in claim 8.
- 34. A method of treating a proliferative disorder comprising the step of administering an antagonist of the polypeptide provided in claim 8.
- 35. The method for preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is a disorder directly linked to aberrant neuropeptide Y receptor activity.
- 36. The method for preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is an eating or appetite disorder.
- 37. The method for preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is a disorder linked to aberrant DNA synthesis.
- 38. The method for preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is a male reproductive disorder.
- 39. The method for preventing, treating, or ameliorating a medical condition of claim 14, wherein the medical condition is testicular cancer.
Parent Case Info
[0001] This application claims benefit to provisional application U.S. Serial No. 60/266,525, filed Feb. 5, 2001; and to provisional application U.S. Serial No. 60/329,897, filed Oct. 16, 2001. The entire teachings of the referenced applications are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60266525 |
Feb 2001 |
US |
|
60329897 |
Oct 2001 |
US |